Abstract
During the last thirty years, part of the scientific community focused on the mechanisms by which a naturally occurring protein called cellular prion (PrPc) converts into a protease-resistant isoform (PrPsc) responsible for fatal Transmissible Spongiform Encephalopathies (TSE). Concomitantly, the physiology of PrPc has also been studied. PrPc undergoes proteolytic attacks leading to both membrane-attached and secreted fragments, the nature of which differs in normal and TSE-affected human brains. Does proteolysis of PrPc correspond to an inactivating mechanism impairing the biological function of the protein, or alternatively, does it represent a maturation process allowing the produced fragments to trigger their own physiological function? Here we review the mechanisms involved in the production of PrPc catabolites and we focus on the function of PrPc and its derived fragments in the cell death/ survival regulation in the nervous system.
Keywords: ADAM, α-secretase-derived fragments, apoptosis, βAPP, cellular Prion protein, neuroprotection, p53, PRNP gene, infectious agent, Creutzfeld-Jacob Disease, synthetic peptide, proteolysis, neurodegeneration, brain pathologies, amyloid plaques
Current Molecular Medicine
Title: Cellular Prion and its Catabolites in the Brain: Production and Function
Volume: 12 Issue: 3
Author(s): M.-V. Guillot-Sestier and F. Checler
Affiliation:
Keywords: ADAM, α-secretase-derived fragments, apoptosis, βAPP, cellular Prion protein, neuroprotection, p53, PRNP gene, infectious agent, Creutzfeld-Jacob Disease, synthetic peptide, proteolysis, neurodegeneration, brain pathologies, amyloid plaques
Abstract: During the last thirty years, part of the scientific community focused on the mechanisms by which a naturally occurring protein called cellular prion (PrPc) converts into a protease-resistant isoform (PrPsc) responsible for fatal Transmissible Spongiform Encephalopathies (TSE). Concomitantly, the physiology of PrPc has also been studied. PrPc undergoes proteolytic attacks leading to both membrane-attached and secreted fragments, the nature of which differs in normal and TSE-affected human brains. Does proteolysis of PrPc correspond to an inactivating mechanism impairing the biological function of the protein, or alternatively, does it represent a maturation process allowing the produced fragments to trigger their own physiological function? Here we review the mechanisms involved in the production of PrPc catabolites and we focus on the function of PrPc and its derived fragments in the cell death/ survival regulation in the nervous system.
Export Options
About this article
Cite this article as:
Guillot-Sestier M.-V. and Checler F., Cellular Prion and its Catabolites in the Brain: Production and Function, Current Molecular Medicine 2012; 12 (3) . https://dx.doi.org/10.2174/156652412799218912
DOI https://dx.doi.org/10.2174/156652412799218912 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of Oligodendrocytes in the Molecular Pathobiology and Potential Molecular Treatment of Cervical Spondylotic Myelopathy
Current Medicinal Chemistry Mechanisms of Control of Neuron Survival by the Endocannabinoid System
Current Pharmaceutical Design Mitochondrial Neuroprotection in Traumatic Brain Injury: Rationale and Therapeutic Strategies
CNS & Neurological Disorders - Drug Targets Targeted Tumor Therapies at a Glance
Current Drug Targets Matrix Metalloproteinase Inhibition in Atherosclerosis and Stroke
Current Molecular Medicine Blockage of Central Sphingosine-1-phosphate Receptor does not Abolish the Protective Effect of FTY720 in Early Brain Injury after Experimental Subarachnoid Hemorrhage
Current Drug Delivery Alcohol Related Changes in Regulation of NMDA Receptor Functions
Current Neuropharmacology APO2L/TRAIL: New Insights in the Treatment of Autoimmune Disorders
Recent Patents on Inflammation & Allergy Drug Discovery Mechanisms of Action of Anesthetics for the Modulation of Perioperative Thrombosis: Evidence for Immune Mechanisms from Basic and Clinical Studies
Current Pharmaceutical Design Chronic Effects of Cocaine on Dopaminergic and Serotonergic Systems of Rats
Current Molecular Imaging (Discontinued) Search and Rescue: Identification of Cannabinoid Actions Relevant for Neuronal Survival and Protection
Current Neuropharmacology Anorexia Nervosa and the Use of Total Parenteral Nutrition Refeeding
Current Nutrition & Food Science Potential Protective Effect of Dl-3-n-butylphthalide on Chronic Cerebral Ischemia Brain Injury
CNS & Neurological Disorders - Drug Targets Cannabinoids and Neuro-Inflammation: Regulation of Brain Immune Response
Recent Patents on CNS Drug Discovery (Discontinued) Polydeoxyribonucleotide (PDRN): A Safe Approach to Induce Therapeutic Angiogenesis in Peripheral Artery Occlusive Disease and in Diabetic Foot Ulcers
Cardiovascular & Hematological Agents in Medicinal Chemistry Therapeutic Potential of Targeting the Endocannabinoids: Implications for the Treatment of Obesity, Metabolic Syndrome, Drug Abuse and Smoking Cessation
Current Medicinal Chemistry Pharmacological Drug Delivery Strategies for Improved Therapeutic Effects: Recent Advances
Current Pharmaceutical Design Toxicological Aspects of Carbon Nanotubes, Fullerenes and Graphenes
Current Pharmaceutical Design From Physiome to Pathome: A Systems Biology Model of Major Depressive Disorder and the Psycho-Immune-Neuroendocrine Network
Current Psychiatry Reviews Extrapulmonary Tuberculosis- Its Management and Control
Current Drug Therapy